South Korea
· Delayed Price · Currency is KRW Prestige Biologics Statistics
Total Valuation
Prestige Biologics has a market cap or net worth of KRW 348.77 billion. The enterprise value is 417.39 billion.
| Market Cap | 348.77B |
| Enterprise Value | 417.39B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Prestige Biologics has 77.42 million shares outstanding. The number of shares has increased by 19.15% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 77.42M |
| Shares Change (YoY) | +19.15% |
| Shares Change (QoQ) | +1.97% |
| Owned by Insiders (%) | 20.29% |
| Owned by Institutions (%) | 0.02% |
| Float | 27.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 173.96 |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.40 |
| EV / Sales | 261.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.60 |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.68.
| Current Ratio | 0.70 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.44 |
| Interest Coverage | -3.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.22% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +13.22% |
| 50-Day Moving Average | 5,972.00 |
| 200-Day Moving Average | 5,143.33 |
| Relative Strength Index (RSI) | 34.66 |
| Average Volume (20 Days) | 210,830 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Prestige Biologics had revenue of KRW 1.60 billion and -25.45 billion in losses. Loss per share was -412.69.
| Revenue | 1.60B |
| Gross Profit | -14.47B |
| Operating Income | -34.83B |
| Pretax Income | -25.45B |
| Net Income | -25.45B |
| EBITDA | -22.47B |
| EBIT | -34.83B |
| Loss Per Share | -412.69 |
Balance Sheet
The company has 36.56 billion in cash and 105.19 billion in debt, giving a net cash position of -68.63 billion or -886.47 per share.
| Cash & Cash Equivalents | 36.56B |
| Total Debt | 105.19B |
| Net Cash | -68.63B |
| Net Cash Per Share | -886.47 |
| Equity (Book Value) | 155.05B |
| Book Value Per Share | 2,002.77 |
| Working Capital | -37.60B |
Cash Flow
In the last 12 months, operating cash flow was -19.51 billion and capital expenditures -4.20 billion, giving a free cash flow of -23.71 billion.
| Operating Cash Flow | -19.51B |
| Capital Expenditures | -4.20B |
| Free Cash Flow | -23.71B |
| FCF Per Share | -306.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,181.40% |
| Pretax Margin | -1,593.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prestige Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.15% |
| Shareholder Yield | -19.15% |
| Earnings Yield | -9.16% |
| FCF Yield | -6.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prestige Biologics has an Altman Z-Score of -0.45. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.45 |
| Piotroski F-Score | n/a |